SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-019287
Filing Date
2022-05-10
Accepted
2022-05-10 16:18:20
Documents
14
Period of Report
2022-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K virx-8k_20220510.htm   iXBRL 8-K 37292
2 EX-99.1 d333155dex991.htm EX-99.1 80467
3 GRAPHIC d333155dlogo.jpg GRAPHIC 13755
  Complete submission text file 0001564590-22-019287.txt   274288

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA virx-20220510.xsd EX-101.SCH 5569
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE virx-20220510_lab.xml EX-101.LAB 19329
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE virx-20220510_pre.xml EX-101.PRE 11471
8 EXTRACTED XBRL INSTANCE DOCUMENT virx-8k_20220510_htm.xml XML 3559
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 22909915
SIC: 2834 Pharmaceutical Preparations